Cell Line Development Services Global Market - Forecast to 2025 - Product Image

Cell Line Development Services Global Market - Forecast to 2025

  • ID: 4375391
  • Report
  • Region: Global
  • 238 Pages
  • IQ4I Research & Consultancy Pvt. Ltd
1 of 5
The Cell Line Development Service Market is Expected to Grow at Double Digit CAGR to Reach $1,214.7 Million by 2025

FEATURED COMPANIES

  • Abeomics
  • Atum
  • Cook Pharmica
  • Gen Target
  • Lonza
  • Sgi-Dna
  • MORE

Cell lines are one the major tools used in research for studying the normal physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and large scale manufacturing of biological compounds. Cell culture is the process by which cells are grown under controlled conditions derived from microbial or animal cells. Cell lines are subculture of primary culture also known as sub-clone. Cell lines derived from primary cultures have a limited life span, after subsequent cultures, cells with the highest growth capacity dominate which are selected for further cell development. Primary cells are cells that are cultured directly from a subject and have a limited lifespan. An immortalized cell line can proliferate indefinitely either through random mutation or deliberate modification which are useful especially for production of therapeutics.

The cell line development service market is expected to grow at double digit CAGR to reach $1,214.7 million by 2025. Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market. Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market. However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.

Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics. The application for cell lines includes research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development. Cell lines are used to produce a wide range of biotherapeutics including vaccine, recombinant proteins that include peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.

Some of the major companies in the cell line development market include: Lonza (Switzerland),Fujifilm Diosynth (Japan), Merck KGaA (Germany), Selexis S.A. (Switzerland), Rentschler Biotech (Germany), Horizon Discovery (U.K.), Sartoris Stedim (France), Wuxi Apptec (China), Boehringer Ingelheim (Germany) and Cook Pharmica (U.S.).

Some of the other players are: Patheon (The Netherlands), Syngene (India), Crown Bioscience (U.S.), Evotec (Germany), Catalent (U.S.), Lake Pharma (U.S.), TCG Lifescience (India), Cobra Biologics (U.K.), Eurofins (Luxembourg ), Abzena (U.K.), JHL Biotech (Taiwan), Charles River Laboratories (U.S.), Genscript (China), Mabplex (U.S.), Trenzyme (Germany), JSR Life Sciences (U.S.), Atum (U.S.), ATCC (U.S.).

The cell line development services global market was estimated region wise, by type of cell lines expression systems, by cell types and by application. This report also contains cost analysis for various cell line development services. Key developments such as collaborations, acquisitions, new launches, partnerships and expansions were reported and analyzed.

  • In depth assessment of all segments and sub segments of cell line development services global market
  • Regional analysis of cell line development services global market
  • Market dynamics for cell line development services global market
  • Cost analysis of different cell line development services and cell based assays
  • Cell line type used in approved biologics (2012-2016) and analysis based on type of modality
  • Comparison matrix of various key players with cell line development capabilities
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeomics
  • Atum
  • Cook Pharmica
  • Gen Target
  • Lonza
  • Sgi-Dna
  • MORE

1 Executive Summary

2 Market Dynamics
2.1 Market Dynamics
2.1.1 Drivers and Opportunities
2.1.1.1 Growing Incidence Rates of Oncology and Immunological Disorders and Increasing R&D Activities Related to the Diseases.
2.1.1.2 Increasing Demand for Biologics and Biosimilars
2.1.1.3 Advanced Technologies for Screening, Cell Line Engineering and Bioprocessing
2.1.1.4 Increasing Number of Cros in Apac Regions
2.1.2 Restraints and Threats
2.1.2.1 Complexities in Development of Stable Cell Lines
2.1.2.2 High Risk of Contamination Due to Complex Purification Method
2.1.2.3 Stringent and Complex Regulations for Biologics in North America and Europe
2.1.2.4 High Cost and Technical Requirements to Obtain Gmp Certifications
2.2 Cell Line Development
2.3 Host Cell Lines

3 Cell Line Development Services Market, by Expression System
3.1 Microbial Expression Systems
3.2 Mammalian Expression System
3.3 Others

4 Cell Line Development Services, by Cell Type
4.1 Cho
4.2 Murine/Mouse Myeloma
4.3 Baby Hamster Kidney (Bhk) Cells
4.4 Hybridoma
4.5 Human Embryonic Kidney (Hek) Cells
4.6 Human Embryonic Retinal Cells (Per.C6)
4.7 Others

5 Cell Line Development Services, by Application
5.1 Research
5.2 Bioproduction
5.3 Diagnostics

6 Cell Line Development Technological Advancements

7 Key Developments

8 Market Share Analysis

9 Company Profiles
9.1 Abzena Plc
9.1.1 Overview
9.1.2 Financials
9.1.3 Service Portfolio
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.2 Boehringer Ingelheim
9.2.1 Overview
9.2.2 Financials
9.2.3 Service Portfolio
9.2.4 Key Developments
9.2.5 SWOT Analysis
9.3 Catalent Inc.
9.3.1 Overview
9.3.2 Financials
9.3.3 Service Portfolio
9.3.4 Key Developments
9.3.5 SWOT Analysis
9.4 Charles River Laboratories
9.4.1 Overview
9.4.2 Financials
9.4.3 Service Portfolio
9.4.4 Key Developments
9.4.5 SWOT Analysis
9.5 Cook Pharmica
9.5.1 Overview
9.5.2 Financials
9.5.3 Service Portfolio
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.6 Crown Biosciences
9.6.1 Overview
9.6.2 Financials
9.6.3 Service Portfolio
9.6.4 Key Developments
9.6.5 SWOT Analysis
9.7 Fujifilm Holdings Corporation
9.7.1 Overview
9.7.2 Financials
9.7.3 Service Portfolio
9.7.4 Key Developments
9.7.5 SWOT Analysis
9.8 Genscript Biotech Corporation
9.8.1 Overview
9.8.2 Financials
9.8.3 Service Portfolio
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.9 Horizon Discovery Group, Plc
9.9.1 Overview
9.9.2 Financials
9.9.3 Service Portfolio
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.1 Jhl Biotech Inc.
9.10.1 Overview
9.10.2 Financials
9.10.3 Service Portfolio
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.11 Lonza Group
9.11.1 Overview
9.11.2 Financials
9.11.3 Service Portfolio
9.11.4 Key Developments
9.11.5 SWOT Analysis
9.12 Merck Kgaa
9.12.1 Overview
9.12.2 Financials
9.12.3 Product Portfolio
9.12.4 Key Developments
9.12.5 SWOT Analysis
9.13 Patheon N.V.
9.13.1 Overview
9.13.2 Financials
9.13.3 Service Portfolio
9.13.4 Key Developments
9.13.5 SWOT Analysis
9.14 Rentschler Biotechnologie Gmbh
9.14.1 Overview
9.14.2 Financials
9.14.3 Service Portfolio
9.14.4 Key Developments
9.14.5 SWOT Analysis
9.15 Sartorius Stedim Biotech S.A
9.15.1 Overview
9.15.2 Financials
9.15.3 Service Portfolio
9.15.4 Key Developments
9.15.5 SWOT Analysis
9.16 Selexis Sa
9.16.1 Overview
9.16.2 Financials
9.16.3 Service Portfolio
9.16.4 Key Developments
9.16.5 SWOT Analysis
9.17 Shanghai Medicilon
9.17.1 Overview
9.17.2 Financials
9.17.3 Service Portfolio
9.17.4 Key Developments
9.17.5 SWOT Analysis
9.18 Shangpharma Corporation /Shanghai Chempartner
9.18.1 Overview
9.18.2 Financials
9.18.3 Service Portfolio
9.18.4 Key Developments
9.18.5 SWOT Analysis
9.19 Syngene International
9.19.1 Overview
9.19.2 Financials
9.19.3 Service Portfolio
9.19.4 Key Developments
9.19.5 SWOT Analysis
9.2 Wuxi Apptec
9.20.1 Overview
9.20.2 Financials
9.20.3 Service Portfolio
9.20.4 Key Developments
9.20.5 SWOT Analysis

List of Tables
Table 1 Cell Line Development Services Market,By Region, (2015-2025) ($Mn)
Table 2 Approved Biologics and Cell Line Type (2012-2016)
Table 3 Number of Approved Biologics by Cell Line Type, (2012-2016)
Table 4 Cell Line Development Services Market, by Expression System, (2015-2025) ($Mn)
Table 5 Cell Line Development Services Market, by Cell Type, (2015-2025) ($Mn)
Table 6 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Table 7 Cell Line Development Services Market, by Application, (2015-2025) ($Mn)
Table 8 Cell Line Development Technologies
Table 9 Cell Line Development Services Cost
Table 10 Key Developments (2015-2017)
Table 11 Comparison Matrix of Cell Line Development Players and Services Offered, (2014-2016) ($Mn)
Table 12 Abzena Plc: Total Revenue and R&D Expenses
Table 13 Abzena Plc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 14 Boehringer Ingelheim: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 15 Boehringer Ingelheim: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 16 Boehringer Ingelheim: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 17 Catalent Inc: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 18 Catalent Inc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 19 Catalent Inc: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 20 Charles River Laboratories: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 21 Charles River Laboratories: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 22 Charles River Laboratories: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 23 Fujifilm Holdings Corporation : Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 24 Fujifilm Holdings Corporation : Total Revenue, by Segments (2014-2016) ($Mn)
Table 25 Fujifilm Holdings Corporation : Total Revenue, by Geography (2014-2016) ($Mn)
Table 26 Genscript Biotech Corporation: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 27 Genscript Biotech Corporation: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 28 Genscript Biotech Corporation: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 29 Horizon Discovery Group: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 30 Horizon Discovery Group: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 31 Horizon Discovery Group: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 32 Lonza Group: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 33 Lonza Group: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 34 Lonza Group: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 35 Merck Kgaa: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 36 Merck Kgaa: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 37 Merck Kgaa: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 38 Patheon N.V.: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 39 Patheon N.V.: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 40 Sartorius Stedim: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 41 Sartorius Stedim: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 42 Shanghai Chempartner: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 43 Syngene International: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 44 Syngene International: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 45 Wuxi Apptec: Total Revenue and R&D Expenses, (2014-2016) ($Mn)

List of Figures
Figure 1 Market Dynamics of Cell Line Development
Figure 2 Cell Line Development Services Market,By Region, (2016) ($Mn)
Figure 3 Number of Approved Biologics by Cell Line Type (2012-2016)
Figure 4 Cell Line Development Services Market,By Expression System, (2016 V’S 2025) ($Mn)
Figure 5 Expression Systems of Some Approved Biologics
Figure 6 Cell Line Development Services Market,By Cell Type, (2016 Vs 2025) ($Mn)
Figure 7 Cell Line Type of Some Approved Biologics
Figure 8 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Figure 9 Cell Line Development Services Market,By Application, (2016 V’S 2025) ($Mn)
Figure 10 Key Developments of Cell Line Development Market Players, 2015-2017
Figure 11 Market Share Analysis, by Cell Line Development Major Players (2016)
Figure 12 Overview: Abzena Plc
Figure 13 SWOT: Abzena Plc
Figure 14 Overview: Boehringer Ingelheim
Figure 15 SWOT: Boehringer Ingelheim
Figure 16 Overview: Catalent Inc.
Figure 17 SWOT: Catalent Inc.
Figure 18 Overview: Charles River Laboratories
Figure 19 SWOT: Charles River Laboratories
Figure 20 SWOT: Cook Pharmica
Figure 21 SWOT: Crown Biosciences
Figure 22 Overview: Fujifilm Holdings Corporation
Figure 23 SWOT: Fujifilm Diosynth Biotechnologies
Figure 24 Overview: Genscript Biotech Corporation
Figure 25 SWOT: Genscript Biosciences Corporation
Figure 26 Overview: Horizon Discovery Group, Plc
Figure 27 SWOT: Horizon Discovery Group, Plc
Figure 28 SWOT: Jhl Biotech Inc.
Figure 29 Overview: Lonza Group
Figure 30 SWOT: Lonza Group
Figure 31 Overview: Merck Kgaa
Figure 32 SWOT: Merck Kgaa
Figure 33 Overview: Patheon N.V.
Figure 34 SWOT: Patheon N.V.
Figure 35 SWOT: Rentschler Biotechnologie
Figure 36 Overview: Sartorious Stedium Biotech S.A.
Figure 37 SWOT: Sartorius Stedium Biotech S.A.
Figure 38 SWOT: Selexis Sa
Figure 39 SWOT: Shanghai Medicilon
Figure 40 SWOT: Shanghai Chempartner
Figure 41 Overview: Syngene International
Figure 42 SWOT: Syngene International
Figure 43 SWOT: Wuxi Apptec

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abeomics
  • Abgenex
  • Abmgood
  • Abzena
  • Acro Biosystems
  • Amgen
  • Amplycell
  • Applied Stem Cell
  • Aragen (Gvk)
  • Atcc
  • Atum
  • Boehringer Ingelheim
  • Bps Bioscience
  • C & M Biolabs
  • Catalent
  • Cellomics Technology
  • Celonic
  • Charles River
  • Chromos Molecular Systems
  • Cobra Biologics
  • Cook Pharmica
  • Creative Biolabs
  • Crown Bioscience
  • Crucell
  • Cytovance Biologics
  • Eurofins
  • Evotec
  • Exonbio
  • Fujifilm Diosynth Biotechnologies
  • Fusion Antibodies
  • G&P Biosciences
  • Gen Target
  • Genscript
  • Glycotope
  • Goodwinbiotechnology
  • Horizon Discovery
  • Jhl Biotech
  • Jsr Life Sciences
  • Kbi Biopharma (Jsr)
  • Lakepharma
  • Lfb Biomanufacturing
  • Lonza
  • Mabplex
  • Merck Kgaa
  • Oxford Genetics
  • Patheon
  • Precision Antibody
  • Probiogen
  • Profacgen
  • Rentschler Biotech
  • Sartorius Stedim Biotech S.A.
  • Selexis
  • Sgi-Dna
  • Sino Biological
  • Speed Biosystem
  • Sydlabs
  • Syngene
  • Tcg Lifesciences
  • Texcell
  • Trenzyme
  • Uga Biopharma
  • Wuxi Apptec
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll